Madrigal's Rezdiffra beats estimates; Gilead cuts jobs; Banyan debuts
🚀 Madrigal Pharmaceuticals' MASH drug beats expectations: The biotech’s Rezdiffra sales came in at $311 million for the first quarter, surpassing analysts’ projections by about $10 million, according to TD Cowen analysts. The Pennsylvania drugmaker ...
Original Source
Read the full article at Endpoints →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.